Skip to main content

Table 1 Main characteristics of studies included on lipid-lowering therapy in the meta-analysis

From: ABCB1 C3435T polymorphism and the lipid-lowering response in hypercholesterolemic patients on statins: a meta-analysis

         

Genotype

First author

Year

Country

Population

Gende (male %)

Age

Follow-up period

Treatment protocal

Lipid

CC

CT

TT

HWE

Fiegenbaum [10]

2005

Brazil

Hypercholesterolemic patients

25.3

59.2 ± 10.7

6 months

simvastatin 20 mg/day

TC LDL-C HDL-C TG

20

45

32

0.570

Hoenig [15]

2011

Australia

Patients recruited with CAD, ischemic stroke, or CAD risk-equivalents

79

67.6 ± 10

6 weeks

atorvastatin 80 mg/day

TC LDL-C HDL-C TG

15

42

41

0.440

Kajinami m [9]

2004

USA

Hypercholesterolemia patients

100

58 ± 11

52 weeks

atorvastatin 10 mg/day

TC LDL-C HDL-C TG

49

101

56

0.793

Kajinami w [9]

2004

USA

Hypercholesterolemia patients

0

58 ± 11

52 weeks

atorvastatin 10 mg/day

TC LDL-C HDL-C TG

36

60

42

0.130

Rodrigues [13]

2005

Brazil

Hypercholesterolemia patients

40.6

59 ± 12

4 weeks

atorvastatin 10 mg/day

TC LDL-C HDL-C TG

19

36

14

0.684

Rosales [12]

2012

Chile

Hypercholesterolemia patients

62.7

56.4 ± 10.7

1 month

atorvastatin 10 mg/day

TC LDL-C HDL-C TG

60

68

14

0.404

Shabana [14]

2013

Egypt

Hypercholesterolemia patients

57

55.2 ± 9.9

4 weeks

atorvastatin 40 mg/day

TC LDL-C HDL-C TG

19

20

11

0.206

Salacka [11]

2014

Poland

NA

43

NA

2-83weeks

atorvastatin 10–20 mg/day, simvastatin 20–40 mg/day

TC HDL-C TG

25

65

40

0.878

  1. NA Not applicable, HWE Hardy-Weinberg equilibrium, TC Total cholesterol, LDL-C Low-density-lipoprotein cholesterol, HDL-C High-density-lipoprotein cholesterol, TG Triglycerides